Kornimate/medical-research-clean huggingface dataset:
a dyadic intervention for young adult patients with cancer and their partner caregivers

Conditions: Cancer; Survivorship; Caregiver Burden; Psychological Distress; Coping Skills; Couples

Summary: the purpose of this pilot study is to examine the feasibility and acceptability of a brief psychotherapy intervention to improve psychosocial coping and maintain couple relationships among young adults (aged 25-39) with cancer and their caregiving partners.

young adults (ya) with cancer have unique challenges in coping, and their primary partners may experience burden and low self-efficacy related to caregiving. in this single-arm pilot trial, the investigators shall deliver an eight-session intervention to yas with cancer and their self-identified partners who provide caregiving. the intervention is founded on principles from cognitive-behavioral therapy and couples-focused interventions, tailored for ya. the aim of the study is to assess the feasibility and acceptability of the intervention, which will inform refinements prior to a larger-scale clinical trial. this study will include 10 yas and their partner-caregivers (n=20). participants will complete surveys at baseline and after the intervention, and will be invited to complete optional semi-structured exit interviews.

Eligibility criteria:
inclusion criteria: * either: (1) currently receiving active cancer treatment (n=5) or are within two years of completing active treatment (n=5) at massachusetts general cancer center (mghcc), located in boston, massachusetts, united states, or (2) are the partner of an individual between the ages of 25-39 who is currently receiving treatment at mghcc (n=5) or who has completed cancer treatment at mghcc within the past two years (n=5) * either: (1) indicates a score ≥4 on the national comprehensive cancer network (nccn) adapted distress thermometer study screening questions, or (2) are the partner of a participant indicating a score ≥4 on the nccn adapted distress thermometer study screening questions * english-speaking exclusion criteria: • uncontrolled psychosis, active suicidal ideation, or cognitive impairment

Keywords: young adult cancer cancer caregiving
randomized comparison of the repneu lung volume reduction coil (lvrc) to standard of care for the treatment of emphysema (reset study)

Conditions: Emphysema

Summary: the objective of this study is to demonstrate the safety and performance of the pneumrx, inc. lung volume reduction coil (lvrc) in a population of patients with emphysema. the pneumrx, inc. lvrc is used as a less invasive alternative to lung volume reduction surgery.


Eligibility criteria:
inclusion criteria: * patient greater than or equal to 35 years of age * high resolution ct scan indicates unilateral or bilateral emphysema * high resolution ct scan indicates homogeneous or heterogeneous emphysema * patient has post-bronchodilator fev1 less than or equal to 45% predicted * total lung capacity greater than 100% predicted * patient has marked dyspnea scoring greater than or equal to 2 on mmrc scale of 0-4 * patient has stopped smoking for a minimum of 8 weeks prior to entering the study * patient (and legal guardian if applicable) read, understood and signed the informed consent form exclusion criteria: * patient has a change in fev1 greater than 20% post-bronchodilator * patients dlco less than 20% predicted * patient has a history of recurrent clinically significant respiratory infection * patient has uncontrolled pulmonary hypertension defined by right ventricular pressure greater than 50mm hg and/or evidenced by echocardiogram * patient has an inability to walk greater than 140 meters (150 yards) in 6 minutes * patient has evidence of other disease that may compromise survival such as lung cancer, renal failure, etc * patient is pregnant or lactating * patient has an inability to tolerate bronchoscopy under heavy sedation or anesthesia * patient has clinically significant bronchiectasis * patient has giant bullae greater than 1/3 lung volume * patient has had previous lvr surgery, lung transplant or lobectomy * patient has been involved in other pulmonary drug studies with 30 days prior to this study * patient is taking greater than 20 mg prednisone (or similar steroid) daily * patient is on plavix or has not been weaned off prior to procedure * patient has other disease that would interfere with completion of study, follow up assessments or that would adversely affect outcomes

Keywords: emphysema repneu
increasing patient comfort in palliative radiotherapy with a newly developed mattress - a prospective clinical study

Conditions: Neoplasms

Summary: the goal of this research is to determine if a new radiotherapy mattress is more comfortable for patients than the standard mattress. the table of the ct scanner and the radiation machine is flat and hard. to increase comfort during the ct scan and radiation dose delivery, the investigators have recently developed a new mattress (rtcomfort). this research aims to find out if the new mattress is more comfortable for patients than the standard matt and to learn how radiotherapy mattresses can be further improved. patients who participate in the research, will be asked to try both the standard mattress and the new mattress during the ct scan appointment. this will take about 5 minutes (one minute each). patients will then be asked which mattress was most comfortable and if they experience any pain while lying on the mattress. patients can choose which mattress will be used for the ct scan and treatment. both mattresses are approved and safe for treatment. if patients participate in the research, it means the investigators will collect and use some of their (medical) data. patients will not have any direct benefits from participating in this research, except that they can choose which mattress they want to lie on. additionally, participation can help us gain more knowledge to make radiotherapy treatment more comfortable. participation in the research will not affect the treatment. participants will receive the normal treatment and check-ups for their condition. the drawback of participating is that the investigators will ask patients to try both mattresses, which will take about 5 minutes.


Eligibility criteria:
inclusion criteria: * age: ≥ 16 * patients treated for bone metastasis in thoracic, abdominal and pelvic region * patients have read, understood and signed the informed consent of the comfort study (in dutch). exclusion criteria: * patients not willing or able to test two mattresses (rt-comfort mattress and standard thin foam matt)

Keywords: radiotherapy palliative radiotherapy radiation oncology comfort pain mattress bone metastasis
the effect of immersive virtual reality treatment with cognitive behaviour therapy for obsessive-compulsive disorder

Conditions: Obsessive-Compulsive Disorder; Virtual Reality

Summary: this study will evaluate the clinical effectiveness ofthe immersive virtual reality alongside exprosure and response prevention (erp) treatment in cognitive-behavioral therapy for obsessive-compulsive disorder, and the underlying neural mechanism by electroencephalography (eeg) and eye-tracking methodology .

the current study aims to the clinical effectiveness of the immersive virtual reality alongside exprosure and response prevention (erp) treatment in cognitive-behavioral therapy for obsessive-compulsive disorder. 30 ocd patients whose symptom were mainly associated with "contamination/clean" , "symmetry/precision", "examination" and "sex" will be randomized into two groups (i.e. vr erp or erp). the treatment will be performed twice a week for the first two weeks. and for the next 4 week, the treatment for ocd patients will be undertook once a week. there will be 8 times in total. the investigators will assess thhe ocd patients'symptom severity in the baseline, 2 weeks, 4weeks and after 8 weeks of the whole combined treatment. through the study, yale-brown obsessive compulsive scale（y-bocs）, the obsessive compulsive inventory-revised (oci-r), the beck depression inventory (bdi), the beck anxiety inventory (bai), perceived stress scale (pss), pittsburgh sleep quality index (psqi) and side-effect questionnaire will be obtained by a trained investigator. the patients will also get individual's data of eeg and eye-movement.

Eligibility criteria:
inclusion criteria: * age: 18-50 years old; * diagnostic and statistical manual of mental disorders (dsm-5) criteria for ocd; * y-bocs total score \> or = 16, discontinued medication for at least 8 weeks before * the enrollment or the paitients' clinical medication is stable for at least a month (the dose and the types of drugs) .\>or＝9 years education exclusion criteria: * any axis i psychiatric disorder comorbidity * participants who have received any forms of psychological therapy in the past. * patients cannot tolerate or adapt to the somatic discomfort caused by vr . * prior history of neurological disease (e.g., epilepsy) or brain surgery for traumatic brain injury * participants with claustrophobic, heart pacemaker, mechanical heart valve, mechanical implant such as an aneurysm clip, hip replacement, or any other pieces of metal that have accidentally entered their body. * any current significant medical condition. * serious suicide risk

Keywords: virtual reality cognitive-behavioral therapy exposure and response /ritual prevention
closed-loop control of glucose levels (artificial pancreas) during postprandial exercise in adults with type 1 diabetes

Conditions: Type 1 Diabetes

Summary: regular physical activity is associated with many health benefits for individuals with type 1 diabetes including improved cardiovascular fitness and vascular health, decreased insulin requirements, improved body composition and quality of life. however, exercise-induced hypoglycemia is very frequent and thus is the main limiting factor for physical activity practice in this population. the artificial pancreas is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's readings. the artificial pancreas has the potential to reduce the risk of exercise-induced hypoglycemia but the importance of announcing exercise to the artificial pancreas is yet to be explored. the objective of this study is to investigate 1) if announcing postprandial exercise to the artificial pancreas is beneficial in reducing the risk of hypoglycemia and 2) if an insulin bolus reduction is necessary when announcing the exercise to the artificial pancreas.


Eligibility criteria:
inclusion criteria: 1. males and females ≥ 18 years of old. 2. clinical diagnosis of type 1 diabetes for at least one year. 3. the subject will have been on insulin pump therapy for at least 3 months. 4. last (less than 3 months) hba1c ≤ 12%. exclusion criteria: 1. clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy as judged by the investigator. 2. recent (\< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery. 3. use of medication with an effect on heart rate (e.g. beta-blockers). 4. abnormal blood panel and/or anemia. 5. ongoing or planned pregnancy. 6. severe hypoglycemic episode within two weeks of screening. 7. other serious medical illness likely to interfere with study participation or with the ability to complete the exercise periods by the judgment of the investigator (e.g. orthopedic limitation). 8. failure to comply with team's recommendations (e.g. not willing to eat snack, not willing to change pump parameters, etc). 9. problems with venous access.

Keywords: closed-loop system artificial pancreas exercise hypoglycemia insulin type 1 diabetes
safety and efficacy of fludarabine and cyclophosphamide + rituximab

Conditions: Follicular Lymphoma

Summary: purpose of this study was to assess the safety profile and the anti-lymphoma activity of the fc+r combination.

the natural history of follicular lymphomas is characterized by a high initial response rate to chemotherapy followed invariably by relapse, with subsequent remissions of progressively shorter duration. the majority of patients eventually die of their disease. as yet, there is no gold standard for the treatment of newly diagnosed or relapsed advanced fl.rituximab(r) has been shown to be a highly effective agent in the treatment of fl, either alone or in combination with chemotherapy. the ability of r to sensitize indolent lymphoma derived cell lines to cytotoxic chemotherapy agents has been demonstrated. furthermore, fludarabine (f) may also sensitize cells to the effects of r. cyclophosphamide (c) and f have shown in vivo synergistic activity. in view of the single agent activity and demonstrated synergy between c and f, and between f and r, we evaluated fc+r in previously treated patients with advanced fl. the primary aim of this study was to assess the safety profile and clinical activity of the fc+r combination. the secondary goal was to evaluate the ability of the treatment to convert bone marrow bcl2 positivity such that patients achieved molecular remissions.

Eligibility criteria:
inclusion criteria: * histologically documented who grade 1-2 ,cd20+,follicular lymphoma * relapsed follicular lymphoma * stage iii or iv disease * stage ii patients are eligible if they present with b symptoms or bulky disease * to have a need for therapy in the opinion of treating clinician * measurable disease * expected survival of 6 months or more * age 18 to 70 years * to have undergone \< 3 lines of chemotherapy * performance status of 0 to 2 exclusion criteria: * known hiv infections * known hepatitis b or c * cns lymphoma * previous malignancies, or cardiac, renal, hepatic, or respiratory failure * pregnant or lactating women and patients of child bearing potential unless using birth control measures

Keywords: follicular lymphoma non-hodgkin lymphoma fludarabine cyclophosphamide rituximab combination immuno-chemotherapy relapsed
effect of hand exercises on hand grip strength and manual ability in children with visual impairment

Conditions: Visual Impairment

Summary: development of the visual system immediately starts after birth via visual stimuli and interactions with the environment. the world health organization (who) has categorized visual impairments with respect to the best-corrected visual acuity as follows: blindness (snellen visual acuity of 3/30), severe visual impairment (snellen visual acuity between 6/60 and 3/30), moderate visual impairment (snellen visual acuity between 6/18 and 6/60), and mild or no visual impairment (snellen visual acuity of 6/18). the proper function of hands, particularly in delicate activities, depends on the interaction between the various regions of the brain, particularly, the sensory and motor cortex. sensory stimulation can be used in such children to improve their manual dexterity and therapeutic interventions can be applied to gain hand strength. developing skillful hands is a necessity in blind children as it often compensates for their missing vision. this study will focus on effectiveness of hand grip strength and manual ability with sensory stimulation in children with moderate to severe visual impairment. theraputty hand exercises and sensory stimulation techniques will be used.

randomised control trial will be conducted with sample size 20. 20 participants will be included in the study. there will be 10 individuals who will receive hand exercises along with sensory stimulation to improve hand grip strength and manual ability and 10 individuals who will only receive hand exercises to improve hand grip strength and manual ability. grip strength and will be analyzed using hand dynamometer. for manual dexterity, box and block test will be used. grip strength and manual dexterity will be analyzed before and after the intervention.group a individuals will only receive hand exercises to improve hand grip strength and manual ability. group b individuals will receive hand exercises along with sensory stimulation to improve hand grip strength and manual ability.

Eligibility criteria:
inclusion criteria: * children diagnosed with moderate (snellen visual acuity between 6/18 and 6/60) to severe (snellen visual acuity between 6/60 and 3/30) congenital visual impairment. (9) * children diagnosed with bilateral congenital visual impairment. (9) * no prior exposure to therapeutic interventions given to hands. (9) * children who can understand english or regional urdu language. (9) * children aged above 6-12 years (9) * children of either gender will be included. exclusion criteria: * children with any orthopedic problem related to hand. (9) * children who went through any surgery of hands or eyes. (9) * children with any neurological issues related to hand. (9) * those who were unable to communicate or unable to hear well .(5). * children diagnosed with complete blindness (snellen visual acuity of 3/30) .(5). * non-co-operative patients

Keywords: hand grip strength sensory stimulation visual impairment
replication of the einstein-pe anticoagulant trial in healthcare claims data

Conditions: Pulmonary Embolism

Summary: investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. the investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

this is a non-randomized, non-interventional study that is part of the rct duplicate initiative (www.rctduplicate.org) of the brigham and women's hospital, harvard medical school. it is intended to replicate, as closely as possible in healthcare insurance claims data, the trial listed below/above. although many features of the trial cannot be directly replicated in healthcare claims, key design features, including outcomes, exposures, and inclusion/exclusion criteria, were selected to proxy those features from the trial. randomization is also not replicable in healthcare claims data but was proxied through a statistical balancing of measured covariates through standard practice. investigators assume that the rct provides the reference standard treatment effect estimate and that failure to replicate rct findings is indicative of the inadequacy of the healthcare claims data for replication for a range of possible reasons and does not provide information on the validity of the original rct finding.

Eligibility criteria:
criteria: please see https://drive.google.com/drive/folders/1wd618wrywyjeaxzfltcuk-vccnb6b-gv for full code and algorithm definitions. inclusion criteria: * confirmed acute symptomatic proximal pe with or without symptomatic dvt exclusion criteria: * legal lower age limitations \[day 0, day 0\] * thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of dvt or pe \[day -14, day 0\] * other indications for vka than dvt and/or pe \[day -180, day 0\] * creatinine clearance \<30 ml/min \[day -180, day 0\] * significant liver disease (e.g. acute hepatitis, chronic active hepatitis, cirrhosis) or alat\>3x uln \[day -180, day 0\] * bacterial endocarditis \[day -180, day 0\] * life expectancy \<3 months \[day -365, day 0\] * active bleeding or high risk for bleeding contraindicating treatment with enoxaparin or vka \[day -180, day 0\] * systolic blood pressure \>180 mghg or diastolic blood pressure \>110mghg \[day -180, day 0\] * childbearing potential without proper contraceptive measures, pregnancy or breastfeeding \[day -180, day 0\] * concomitant use of strong cyp3a4 inhibitors (e.g. hiv protease inhibitors, systemic ketoconazole) or strong cyp3a4 inducers rifampin \[day -14, day 0\]
study evaluating desvenlafaxine succinate sustained release (dvs sr) in the treatment of major depressive disorder

Conditions: Major Depressive Disorder

Summary: the primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of dvs sr (25 and 50 mg/day) in the treatment of adults with major depressive disorder. the study will also assess changes in sexual function and general and functional quality of life outcomes.


Eligibility criteria:
inclusion criteria: * adult, outpatient with primary diagnosis of major depressive disorder (depressive symptoms for at least 30 days prior to screening) * hamilton psychiatric rating scale for depression (ham-d 17) total score of \>= 20 * clinical global impressions scale-severity (cgi-s) score of \>= 4 exclusion criteria: * clinical instability - 25% or greater increase/decrease in ham-d 17 total score from screening to baseline * significant risk of suicide as assessed by clinician judgement, ham-d 17 and columbia suicide-severity rating scale scores other eligibility criteria also apply

Keywords: major depressive disorder
ultrasound assessment of rheumatoid arthritis patients who changed diet

Conditions: Rheumatoid Arthritis; Overweight

Summary: the purpose of this research study is to evaluate if a weight loss intervention will improve your rheumatoid arthritis disease activity.

this is a pilot 12-week rct (randomized clinical trial) in 60 obese ra (rheumatoid arthritis) patients to evaluate if a weight loss intervention will improve pdus (power doppler ultra sound), traditional disease activity measures (das28, disease activity score - 28), and adipokine/mbda (multi-biomarker disease activity) assessments. while there have been observational weight loss ra studies, none were rcts and they did not utilize objective measures (pdus or mbda).

Eligibility criteria:
inclusion criteria: 1. patient must meet 1987 acr (american college of rheumatology) criteria 2. age \> 18 years of age 3. baseline das28/esr\>3.2 (esr-erythrocyte sedimentation rate) 4. stable dmards or biologic therapy for at least 12 weeks, or stable off ra therapy 12 weeks. 5. willingness to participate in a weight loss program 6. bmi \> 30 7. prednisone ≤ 10 mg 8. patient has provided informed consent exclusion criteria: 1. major surgery (including joint surgery) within 8 weeks prior to baseline or planned major surgery within 3 months after baseline 2. evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease 3. known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (as this may falsely elevate biomarkers) 4. any major episode of infection requiring hospitalization or treatment with iv antibiotics within 4 weeks of baseline or oral antibiotics within 2 weeks prior to baseline 5. pregnant women or nursing (breast feeding) mothers 6. neuropathies or other conditions that might interfere with pain evaluation unless related to primary disease under investigation 7. history of an eating disorder 8. history of bariatric surgery 9. ekg results deeming patient to unsafe for study intervention 10. allergy to study intervention

Keywords: rheumatoid arthritis (ra) musculoskeletal ultrasound (msus)